EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitVergleichsstudieLeitlinieOpen Access · CC BY 4.0

Updated Guidelines for the Prevention and Management of Chronic Hepatitis B—World Health Organization 2024 Compared With China 2022 HBV Guidelines

Grace Lai-Hung Wong iD

Journal of Viral Hepatitis · 2024-12 · 31 (S2) · 13-22

DOI: 10.1111/jvh.14032 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Viral Hepatitis, online erschienen am 06.11.2024. Verfasst von Grace Lai-Hung Wong. Beteiligte Einrichtung: Department of Medicine and Therapeutics, Medical Data Analytics Centre, Hong Kong, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, World Health Organization, Antiviral Agents, Practice Guidelines as Topic. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The year 2024 is the year of new clinical practice and management guidelines for chronic hepatitis B virus (HBV) infection. World Health Organization (WHO) published the updated HBV guidelines in March 2024. In contrast, two key international societies for liver diseases, including the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL), are currently in the process of updating their clinical practice guidelines for HBV. In 2022, China published their HBV guidelines, regarded as one of the most uncompromising ones as the threshold to start antiviral treatment is set at detectable HBV DNA above 10–20 IU/mL. In this chapter, the latest developments in the HBV guidelines with a specific focus on the Chinese & WHO guidelines are discussed. Specifically, the pros and cons of lowering treatment thresholds and the benefits of treating more people to avoid the complications of chronic hepatitis B, specifically HCC, are reviewed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicWorld Health OrganizationAntiviral AgentsPractice Guidelines as TopicHumansChinaHepatitis B virusDisease ManagementDNA, Viral

Stichwörter der Autor:innen

HBV DNAalanine aminotransferaseantiviral therapyhepatocellular carcinomamother‐to‐child transmission

Substanzen

Antiviral AgentsDNA, Viral

Autor:innen und Institutionen

  • Department of Medicine and Therapeutics, Medical Data Analytics Centre, Hong Kong, China.
  • State Key Laboratory of Digestive Disease, Institute of Digestive Disease The Chinese University of Hong Kong, Hong Kong, SAR, China.

ORCID-Profile: Grace Lai-Hung Wong

Zitieren

APA

Wong, G. L. (2024). Updated Guidelines for the Prevention and Management of Chronic Hepatitis B—World Health Organization 2024 Compared With China 2022 HBV Guidelines. Journal of Viral Hepatitis, 31(S2), 13-22. https://doi.org/10.1111/jvh.14032

Vancouver

Wong GL. Updated Guidelines for the Prevention and Management of Chronic Hepatitis B—World Health Organization 2024 Compared With China 2022 HBV Guidelines. Journal of Viral Hepatitis. 2024;31(S2):13-22. doi:10.1111/jvh.14032

BibTeX
@article{Wong2024,
  author = {Wong, Grace Lai-Hung},
  title = {Updated Guidelines for the Prevention and Management of Chronic Hepatitis B—World Health Organization 2024 Compared With China 2022 HBV Guidelines},
  journal = {Journal of Viral Hepatitis},
  year = {2024},
  volume = {31},
  number = {S2},
  pages = {13--22},
  doi = {10.1111/jvh.14032}
}
Kostenlos starten →